Posted by Michael Wonder on 24 Jun 2023
AbbVie secures positive CHMP opinion for atogepant for the preventive treatment of adults with migraine
23 June 2023 - The positive CHMP opinion is based on results from two pivotal Phase 3 studies evaluating atogepant for the prophylaxis of migraine in adults with episodic or chronic migraine.
AbbVie today announced that the EMA's CHMP has adopted a positive opinion recommending the approval of atogepant for the prophylaxis of migraine in adults who have four or more migraine days per month.
